1.In 1980, two years after Plana's work on Glucosamine HCl, Rotta Research Laboratories began sponsoring a series of clinical trials utilizing Glucosamine Sulfate as the preferred therapeutic drug for osteoarthritis. Rotta claims that the sulfate from the glucosamine is beneficial but does not offer any science to support this contention. In fact, the published work shows no preference for the sulfate over the hydrochloride.
2.Glucosamine offers relief for knee pain:People reported better pain relief and improved function if they took the glucosamine (British Journal of Sports Medicine 2003; 37: 45-49).
3.Glucosamine Stops Knee Arthritis in Women In the latest of an ongoing series of studies, European researchers studied the effect of glucosamine specifically in postmenopausal women already diagnosed with knee osteoarthritis. After the age 50, knee osteoarthritis becomes more common in women -- possibly because of waning estrogen levels . Osteoarthritis, caused by degeneration of cartilage that occurs with age, is the most common type of arthritis. (Bruyere, O, Menopause, March/April 2004; vol 11: pp 138-143. Pavelka, K, Archives of Internal Medicine, Oct. 14, 2002; vol 162: pp 2113-2123.)
Fifteen studies were included, with data on 1,775 patients (1,020 glucosamine and 755 chondroitin). Quality scores were high, and were higher for glucosamine trials (all scored 4 or 5 out of 5) than chondroitin trials (all scored 3, 4 or 5 out of 5, except one with insufficient details for scoring).
Glucosamine doses were mostly 1,500 mg daily. Trial duration was 6-8 weeks to three years. Chondroitin doses 800 to 2,000 mg daily, in trials of three months to one year.
The main results are shown in Table below. Glucosamine significantly reduced joint space narrowing by about 0.27 mm compared with placebo over three years with 1,500 mg daily. Glucosamine and chondroitin improved continuous outcomes measured using the Lequesne index, the WOMAC index, and pain and mobility. The minimal differences between treatment and placebo were 2.1 points (1.5 to 2.7) for the Lequesne index, and 13 mm (10 to 16 mm) for pain after 90 days of treatment.